In addition, future studies should now explore whether the XOR inhibitors allopurinol or febuxostat will, in practice, at least as adjuvant strategies, reduce the risk of conversion from CIS to definite MS, the number of relapses and disability progression since people with gout very rarely develop MS which we think could be due to the effect of the treatment rather than the elevated UA levels. Here, XDH is linked to myeloid sarcoma.